Literature DB >> 33334281

Envisioning the Future of Nanomedicines in Management and Treatment of Neurological Disorders.

Shobhit Kumar1, Priyanka Singh2, Shrestha Sharma3, Faheem H Pottoo4, Javed Ali5, Sanjula Baboota5.   

Abstract

Neurodegenerative disorders are a result of continuous deterioration of the structure and function of neurons, involving the death of neurons. Neurodegenerative disorders affect millions of people around the world. Several conventional drug delivery strategies are available to treat neurological disorders. However, they are unable to provide adequate cytoarchitecture restoration and connection patterns due to lower solubility, poor bioavailability, drug resistance and incapability to traverse the blood-brain barrier (BBB). Therefore, designing and developing new and efficient delivery systems, that can bring drugs to CNS and have good bioavailability in the brain is very important. Nano drug delivery system acts as a ray of hope in the diagnosis and treatment of neurological disorders. The use of nanomedicines encapsulating therapeutic molecules may enhance transport of drug across BBB, absorption of drug and its controlled release in the human body with minimum adverse effects. This review article includes a comprehensive overview of the BBB, recent developments and application of nanomedicines, including liposomes, nanoparticles, nanomicelles, carbon nanotubes, etc., to the management as well as clinical therapy of various neurodegenerative disorders. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Nanomedicines; central nervouszzm321990system.; nanocrystals; nanoparticles; neurodegenerative disorders; neurological disorder

Mesh:

Substances:

Year:  2021        PMID: 33334281     DOI: 10.2174/1386207323666201217151132

Source DB:  PubMed          Journal:  Comb Chem High Throughput Screen        ISSN: 1386-2073            Impact factor:   1.339


  1 in total

Review 1.  The Role of Natural Products as Inhibitors of JAK/STAT Signaling Pathways in Glioblastoma Treatment.

Authors:  Hanieh Fahmideh; Hooriyeh Shapourian; Rasol Moltafeti; Chanour Tavakol; Razieh Forghaniesfidvajani; Hamidreza Zalpoor; Mohsen Nabi-Afjadi
Journal:  Oxid Med Cell Longev       Date:  2022-09-19       Impact factor: 7.310

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.